It is important to identify selective ligands for the estrogen receptor subtypes ERα or ERβ to evaluate them as pharmaceutical targets in breast cancer. To develop ERβ-selective ligands as PET imaging agents, a series of aryl indazole estrogen analogues substituted at the C3 position with fluoroethyl and fluoropropyl groups were synthesized and evaluated for their relative binding affinities and selectivities for ERα vs ERβ. The fluoroethylated indazole estrogen (FEIE, 1i) and fluoropropylated indazole estrogen (FPIE, 1h) showed 41-fold and 17-fold ERβ/ERα selectivity, respectively. However, their binding affinities to ERα and ERβ were very low.
Introduction
Estrogens play an essential role in the growth, development, and homeostasis of various reproductive and nonreproductive target tissues.
1 Estrogens exert many of their actions via estrogen receptors (ERs), which function as ligand-regulated transcription factors. 2 The discovery of the ERs (ERα was cloned in 1986 3 and ERβ in 1996 4 ) prompted intensive studies on the respective functions of the two receptor subtypes. Most estrogen target tissues contain both ERα and ERβ, although in varying ratios; ERα is widely expressed in breast and uterine tissue, whereas ERβ is found at higher levels in lung, ovary, prostate, bone, vascular epithelium and certain brain regions. While it is difficult to generalize, ERβ is usually less active as a transcription factor and exerts a restraining effect on the more active ERα. 5 Although normal breast tissue contains both ERα and ERβ, in breast tumors, the level of ERβ relative to ERα declines with disease progression, as one might expect, with transition of the cancer to a more proliferative and malignant state. 6 Thus, if the independent quantification of ERα and ERβ levels in breast cancer could be achieved by imaging non-invasively, using radioisotope-labeled ER subtypeselective ligands with positron emission tomography (PET) or single photon emission computed tomography (SPECT), it might provide predictive information for disease staging and tumor response to hormone therapies.
The two ERs subtypes share about 60% amino acid identity in their ligand binding domains (LBD), 7 and the volume of the ERβ ligand binding pocket is smaller than that of ERα. 8, 9 Otherwise, the ligand-binding pockets are very similar, with the amino acids lining the ERβ pocket differing from those of ERα by only 2 out of 24 residues, Leu 384 and Met 421 in ERα being replaced by Met 336 and Ile 373 in ERβ, respectively. 9 Despite this similarity, it has proved possible to develop ER ligands that bind to and activate either ERα or ERβ with a high level of selectivity, and a reasonable pharmacophore model has been advanced to guide the design of subtype-selective ligands. Compounds with good selectivity for ERα have been reported in the literature, including pyrazole-, pyrrole-, and furan-core derivatives, 10 and ERβ-selective ligands with varying core structures have also been reported, such as tetrahydrochrysenes, diarypropionitriles, cyclofenils, benzothiophene, benzothiazoles, benzimidazoles, benzoxazoles and benzofused heterocyclic analogues.
11 Various estrogen derivatives have been developed as radioisotope-labeled PET or SPECT imaging agents for the diagnosis, treatment and monitoring response to hor- mone therapy in breast cancer. Thus far, however, success in developing imaging agents selective for ERα 12 or ERβ 13 that performs well in vivo has been limited. Therefore, differential imaging of the two ER subtypes remains a major challenge.
Recently, Katzenellenbogen et al. reported that compounds having a phenyl-2H-indazole core structure showed good selectivity for ERβ in terms of receptor binding and potency in transcription assay (Figure 1 ).
14 These compounds appeared to be promising agents for the selective interaction with and activation of ERβ. Another attractive feature of this heterocyclic system is that it is possible to introduce various groups (halogen, alkyl, cyano, etc., 1a-f, Figure 1 ) at an internal position of the heterocyclic system (C3). Thus, on the basis of these biological results, we designed fluoroalkylated indazole core estrogens as potential ERβ-selective imaging agents. Herein, we describe the synthesis and biological evaluation of fluoroethyl and fluoropropyl C3 substituted indazole estrogens, based on the phenyl-2H-indazole pharmacophore, as ERβ-selective PET tracer candidates.
Experimental
Materials. All commercial reagents and solvents were used without further purification unless otherwise specified. Solvents and reagents were commercially purchased from Aldrich (USA) and Merck Co. (Germany). Thin layer chromatography (TLC) was performed on Merck 60 F-254 silica plates and visualized by UV. Flash column chromatography was performed on silica gel (Merck, 230-400 mesh ASTM). 1 H NMR and 13 C NMR spectra were recorded on a Bruker-300 and are reported in parts per million downfield from internal tetramethylsilane. Mass spectra were obtained on a JMS700 spectrometer (JEOL Co., Japan). Indazole core and known compound were synthesized following the reported procedure with a little modification and characterized by 1 H and 13 C NMR. 14, 15 1-(2-Bromo-5-methoxybenzyl)-1-(4-methoxyphenyl)-hydrazine (4). To a solution of NaHMDS (45.8 mL, 1.0 M/ THF, 45.8 mmol) at 0 o C was added 4-methoxyphenylhydazine hydrochloride (3) (4.0 g, 22.9 mmol) under an Ar atmosphere. After 15 min, the ice bath was removed and the reaction mixture was stirred for 1 h at room temperature. The reaction mixture was re-cooled to 0 o C, and then the 2-bromo-5-methoxybenzylbromide (2, 6.4 g, 22.9 mmol) was slowly added. After the reaction mixture was stirred at room temperature for 1 h, it was then quenched with water. The mixture was extracted with ethyl acetate and the organic layer was dried over sodium sulfate and purified by flash column chromatography (30% EtOAc/hexane) to give 4 as a yellow oil: 
3-(3-Fluoropropyl)-5-hydroxy-2-(4-hydroxyphenyl)-2H-indazole (1h, FPIE).
This material was prepared by a procedure similar to that used for the preparation of compound 10a, described above: tosylate 9b (60 mg, 0.11 mmol) and TBAF·3H 2 O (72 mg, 0.23 mmol) were dissolved in anhydrous acetonitrile and stirred at 90 o C for 30 min. The reaction mixture was extracted with ethyl acetate and combined organic layer was dried over sodium sulfate and concentrated. The crude product was purified by flash column chromatography (20% EtOAc/hexane) to give 10b (86%) as a pale yellow oil. The collected product 10b was dissolved in CH 3 CN. To a stirred mixture, 1 N HCl (0. 
5-(Methoxymethoxy)-2-(4-methoxymethoxyphenyl)-3-vinyl-2H-indazole (7c).
This material was prepared by a procedure similar to that used for the preparation of compound 7b, described above: solution of 6b (300 mg, 0.77 mmol) in anhydrous 1,4-dioxane was added vinyltributyltin (0.40 mL, 1.38 mmol), CsF (258 mg, 1.7 mmol) and Pd(P(tBu) 3 ) 2 (12 mg, 3 mol%). After 4 h at 100 o C, reaction mixture was extracted with ethyl acetate and dried over sodium sulfate. The combined organic layer was purified by flash column chromatography (25% EtOAc/hexane) to give 7c (78%) as a yellow oil: 
5-(Methoxymethoxy)-2-(4-methoxymethoxyphenyl)-3-(3-p-toluenesulfonyloxypropyl)-2H-indazole (9c).
According to the procedure for the preparation of compound 9a described above, tosylate 8c (110 mg, 0.31 mmol) was dissolved in dichloromethane. To a stirred mixture, p-toluenesulfonic anhydride (200 mg, 0.61 mmol) and pyridine (73 μL, 0.9 mmol) were added and stirred at room temperature for 2 h. The reaction mixture was extracted with ethyl acetate and combined organic layer was dried over sodium sulfate and concentrated. The crude product was purified by flash column chromatography (40% EtOAc/hexane) to give 9c (91%) as a pale yellow oil: Estrogen receptor binding affinity assays. Relative binding affinities were determined by a competitive radiometric binding assay as previously described, 16 
Results and Discussion
Synthesis. Synthesis of the indazole core structure was accomplished following a known procedure. 15 Treatment of phenylhydrazine 3 with sodium hexamethyl disilyl amide followed by the o-bromobenzyl bromide 2 provided the alkylated derivative 4 (Scheme 1). This was cyclized in a palladium-catalyzed coupling reaction and was then oxidized in situ to furnish the protected indazole derivative 5. To prepare the desired fluoroalkyl analogues, we developed methods to introduce substituents at C3 that would contribute a vinyl or allyl moiety from which the fluoroethyl and fluoropropyl groups could be prepared. Since the C3 position can be easily halogenated, bromo-indazole derivative 6a was obtained by treatment of the core system 5a with NBS.
To prepare the allyl-substituted product 7a, we used a Stille coupling reaction with allyltributyltin, Pd 2 (dba) 3 , P(tBu) 3 , and CsF (Scheme 1). Although the corresponding iodo-indazole derivative could also be prepared by treating compound 5 with I 2 , the only compound obtained under diverse Pd catalyst-mediated Stille coupling reaction conditions was the deiodinated compound 5, with no formation of the allylated compound 7a being evident. Hydroboration of alkene 7a using borane-THF complex in THF at 0 o C for 2 h and subsequent oxidation with alkaline peroxide gave the aliphatic alcohol 8a, which was converted the corresponding tosylate 9a. The ether-protected fluoropropyl compound 10a was prepared from the tosylated precursor 9a, using TBAF· 3H 2 O. However, when we tried to deprotect methyl ether groups using various demethylation reagents such as BF 3 17 as well as others (Scheme 1), we were unable to obtain the desired fluorobisphenol without also cleaving the C-F bond. This necessitated a change to a more easily cleaved protecting group.
As a new protecting group, we selected the MOM group because it should be stable during the fluorination step, which is conducted under basic conditions, yet can be rapidly removed under relatively mild acidic conditions. Our second synthesis began with deprotection of the methyl groups in intermediate 6a (Scheme 2). This was successfully achieved under typical BBr 3 conditions to give the bromobisphenol 1b, which was then reprotected with MOMCl and NaH condition to give the MOM-protected analog 6b. Allylated 7b was prepared from the MOM-protected 3-bromoindazole 6b by the Still reaction using Pd(P(t-Bu) 3 ) 2 and allyltributyltin. Hydroboration of 7b with BH 3 ·THF followed by treatment with aqueous NaOH/H 2 O 2 converted the alkene 7b into the terminal alcohol 8b, which was converted to the tosylate, giving the fluorination precursor 9b. Subsequently, fluorination to give 10b was achieved by employing reaction conditions similar to those shown in Scheme 1. Deprotection of the MOM groups in 10b was easily achieved by treatment with 1 N HCl to give final product fluoropropylated indazole estrogen (FPIE, 1h) .
For the synthesis of the tosylated precursor for fluoroethylated indazole estrogen (FEIE, 1i) (Scheme 3), Stille coupling of the MOM-protected bromoindazole 6b with vinyltributyltin, hydroboration, followed by oxidation and tosylation of primary alcohol, were achieved under reaction conditions similar to those shown Scheme 2. To prepare an unlabeled authentic sample, the hydroxy group in compound 8c was converted to fluorine using DAST to give, after MOM deprotection, the desired fluoroethylated indazole estrogen (FEIE, 1i) in < 10% yield. Fluorination of 9c with TBAF·3H 2 O was achieved in < 3% yield, with the vinyl compound 7c, resulting from elimination, being the major reaction product. Despite the low yields obtained in both of these fluorination reactions, MOM-protected FEIE (10c) can be synthesized efficiently from the tosylated precursor 9c in 68% yield, using CsF in tert-BuOH, novel fluorination conditions that we have recently described. Table 1 .
The indazole estrogen derivatives substituted at C3 with either fluoroethyl or fluoropropyl groups were investigated. The affinity of the fluoropropylated indazole estrogen (FPIE, 1h) for ERα is only 0.005% that of estradiol, while its affinity for ERβ is around 0.087%, giving an ERβ affinity selectivity of 17.4 fold based on comparison of RBA values. With the fluoroethylated indazole estrogen (FEIE, 1i) , the affinity for ERα (0.003%) is slightly lower than that of FPIE (1h), while its affinity for ERβ was 0.124%, giving it an ERβ selectivity of 41.3 fold, which is actually higher than that of the fluoropropyl-substituted analog. Thus, in terms of both ERβ binding affinity and selectivity, the fluoroethyl derivative (FEIE, 1i) is better of two fluoroalkyl indazoles.
The substitution of the indazole system at C3 with these fluoroalkyl groups (as in FPIE, 1h and FEIE, 1i) rather than halogens (1a-c) or alkyl, nitrile, or other groups (1d-g), led to a very marked reduction in affinity, although strong ERβ affinity selectivity still persisted. From the binding trends shown in Figure 1 , it is clear that as the length of an alkyl substituent increase, binding affinity drops (compare ethyl 1f vs. propyl 1g). In addition, although ERβ seems more tolerant of interior polarity, 11 as a general rule, polar substituents are generally not preferred in the interior of estrogen ligands. 19 Given the polar nature of a single fluorine substituent, it is therefore not surprising, in retrospect, that both FPIE (1h) and FEIE (1i) are relatively low affinity ligands for both ERs. These indazole estrogens, therefore, are not adequate as a PET imaging radiotracer and further investigation needs.
In summary, we have prepared two novel 2-phenyl-2H-indazoles having fluoroethyl-and fluoropropyl side chain as PET tracer candidates for the imaging of estrogen receptor b. Both fluoroalkyl derivatives showed low binding affinity values for ERα and ERβ. However, the fluoroethyl analog, FEIE (1i) showed good relative binding affinity selectivity for ERβ (41.3-fold ERβ selective). It is possible that modification of indazole estrogens at the C3', C6, or C7 position might lead to compounds with better estrogen receptor binding affinities than those modified at the C3 position. Further investigations of such derivatives might be fruitful. 
